



Yale 204-RSB:jr
OCR 133
SY 9492

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Tai-Shun Lin and William Prusoff
Serial No. : 06/942,666
Filed : December 17, 1986
For : USE OF 3'-DEOXYTHYMIDIN-2'-ENE (3'-
DEOXY-2',3'-DIDEHYDROTHYMIDINE) IN
TREATING PATIENTS INFECTED WITH
RETROVIRUSES
Art Unit : 183
Examiner : Dr. John W. Rollins

Hon. Commissioner of Patents
and Trademarks,
Washington, D.C. 20231

Sir:

DECLARATION UNDER RULE 132

Colin McLaren declares that:

1. All statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. That in my Declaration Under Rule 132 dated September 22, 1989, that the compound identified as "d4T"

should have been identified as 3'-deoxythymidin-2'-ene(3'-deoxy-2',3'-didehydrothymidine).

3. That such compound utilized in the experiments described in my Declaration of September 22, 1989 was the same compound recited in the specification and claims of U.S. Patent application Serial No. 06/942,666, namely 3'-deoxythymidin-2'-ene(3'-deoxy-2',3'-didehydrothymidine).

4. That in my opinion, the experiments described in my Declaration of September 22, 1989 concerning CD4 cell counts, HIV p24 antigen and body weights clearly demonstrate a benefit to humans when compound d4T is administered to humans infected with HIV.

Date Dec 19th, 1989.

Colin McLaren
Colin McLaren, Ph.D
MRC Path